Search Results
Feb 11, 2026, 17:31 ET EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight
therapies, such as ArriVent BioPharma (NASDAQ: AVBP), Akeso Biopharma (HKG: 9926), Summit Therapeutics (NASDAQ: SMMT), J INTS BIO, Merus (NASDAQ: MRUS), Merck (NYSE: MRK), Kelun-Biotech (HKG: 6990), Genprex (NASDAQ: GNPX), Cullinan Oncology (NASDAQ: CGEM), Taiho Pharma, CSPC Pharmaceutical (HKG: 1093),
More news about: DelveInsight Business Research, LLP
Jan 13, 2026, 03:00 ET Xsens IMUs deliver sub-5 cm real-time Heave accuracy for precise wave motion compensation
Reference Units (MRUs) – IMUs with Heave capability – deliver real-time Heave accuracy better than 5cm for wave periods up to 29s. This covers most marine applications. For longer wave periods up to 40s, accuracy is approximately 6cm, twice the range supported by comparable industrial-grade MRUs."Engineers
More news about: Xsens
Dec 16, 2025, 13:17 ET Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B
Biotech Inc. (NASDAQ: ONCY), AIM ImmunoTech (NYSE-American: AIM), ArriVent BioPharma, Inc. (NASDAQ: AVBP), Merus N.V. (NASDAQ: MRUS), and Halozyme Therapeutics, Inc. (NASDAQ: HALO) as potential leaders in the battle against stolid tumors, including gastrointestinal cancers.
More news about: USA News Group
Nov 21, 2025, 17:30 ET $HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-MRUS, ACLS, VECO, and CLCO
MRUS) related to its sale to GEnmad A/S. Under the terms of the proposed transaction, Merus stockholders will receive $97.00 in cash per share.ACT
More news about: Monteverde & Associates PC
Nov 17, 2025, 07:00 ET Merus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab
Merus N.V. (Nasdaq: MRUS) ("Merus"), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics®
More news about: Halozyme Therapeutics, Inc.
Nov 12, 2025, 13:55 ET Halper Sadeh LLC Encourages HSII, MRUS, ATXS Shareholders to Contact the Firm to Discuss Their Rights
multimedia:https://www.prnewswire.com/news-releases/halper-sadeh-llc-encourages-hsii-mrus-atxs-shareholders-to-contact-the-firm-to-discuss-their-rights-302613321.html
More news about: Halper Sadeh LLP
Nov 05, 2025, 12:35 ET Halper Sadeh LLC Encourages TIPT, MRUS, PBBK Shareholders to Contact the Firm to Discuss Their Rights
multimedia:https://www.prnewswire.com/news-releases/halper-sadeh-llc-encourages-tipt-mrus-pbbk-shareholders-to-contact-the-firm-to-discuss-their-rights-302605760.html
More news about: Halper Sadeh LLP
Nov 04, 2025, 21:00 ET $HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate Merger - MRUS, HSII, PRO, and PBBK
MRUS) related to its sale to GEnmad A/S. Under the terms of the proposed transaction, Merus stockholders will receive $97.00 in cash per share.
More news about: Monteverde & Associates PC
Oct 21, 2025, 21:51 ET Halper Sadeh LLC Investigates FSFG, MTSR, VRNT, MRUS on Behalf of Shareholders
multimedia:https://www.prnewswire.com/news-releases/halper-sadeh-llc-investigates-fsfg-mtsr-vrnt-mrus-on-behalf-of-shareholders-302590760.html
More news about: Halper Sadeh LLP
Oct 21, 2025, 17:30 ET $HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate Merger - FSFG, MTSR, VRNT, and MRUS
MRUS) related to its sale to GEnmad A/S. Under the terms of the proposed transaction, Merus stockholders will receive $97.00 in cash per share.
More news about: Monteverde & Associates PC
Oct 03, 2025, 11:09 ET SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates EA, MRUS, VECO on Behalf of Shareholders
multimedia:https://www.prnewswire.com/news-releases/shareholder-investigation-halper-sadeh-llc-investigates-ea-mrus-veco-on-behalf-of-shareholders-302574767.html
More news about: Halper Sadeh LLP
Sep 30, 2025, 17:30 ET $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of 1st Merus N.V. (NASDAQ: MRUS)
MRUS) related to its sale to GEnmad A/S. Under the terms of the proposed transaction, Merus stockholders will receive $97.00 in cash per share. Is
More news about: Monteverde & Associates PC
Sep 30, 2025, 03:30 ET EQT Life Sciences portfolio company Merus to be acquired by Genmab in an all-cash USD 8.0 billion transaction
venture capital firm, is pleased to share that Genmab (CPH: GMAB) has entered into a definitive agreement to acquire its portfolio company Merus (NASDAQ: MRUS) for a total consideration of USD 8.0 billion. This transaction represents one of the largest M&A deals in European biotech and underscores the value
More news about: EQT
Sep 29, 2025, 12:30 ET SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates EA, MRUS, HFWA, TIPT on Behalf of Shareholders
multimedia:https://www.prnewswire.com/news-releases/shareholder-investigation-halper-sadeh-llc-investigates-ea-mrus-hfwa-tipt-on-behalf-of-shareholders-302569524.html
More news about: Halper Sadeh LLP